Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an announcement.
ImmuneOnco Biopharmaceuticals announced its unaudited consolidated interim results for the first half of 2025, highlighting significant progress in its oncology drug pipeline. The company completed patient enrollment and achieved primary endpoints in Phase II clinical trials for its core product, IMM01, in combination with azacitidine for treating higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, demonstrating promising efficacy and tolerability.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative oncology products. The company is engaged in advancing its drug pipeline, particularly in the area of cancer treatment, with a market focus on high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Average Trading Volume: 4,153,451
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.6B
See more insights into 1541 stock on TipRanks’ Stock Analysis page.